Related Experiment Videos
Rheumatoid arthritis: guidelines for emerging therapies
1Gralyn Health Associates Inc, PO Box 2634, Farmington Hills, MI 48333, USA. snblumberg@msn.com
Abstract:
The individual and societal impacts of rheumatoid arthritis are of substantial consequence. Management of the disease has pharmacologically focused on the use of anti-inflammatories and disease-modifying antirheumatic drugs, which are only partially successful in retarding joint destruction and functional disability. The recent emergence of cytokine antagonists (anti-tumor necrosis factor therapy) challenges clinicians and managed care organizations with the need to develop new treatment guidelines. Recent developments in the understanding of rheumatoid arthritis, including its epidemiological characteristics, economic costs, clinical progression, and current and emerging therapies, are reviewed. Pharmacologic utilization models are proposed. Pending the development of broad-based consensus treatment recommendations, interim treatment guidelines are suggested.
Insights
Rheumatoid arthritis management is evolving with new biologic therapies like anti-tumor necrosis factor treatments. This review covers current understanding and suggests interim guidelines for rheumatoid arthritis treatment.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) causes significant individual and societal burdens.
- Current RA treatments, including anti-inflammatories and disease-modifying antirheumatic drugs (DMARDs), offer partial efficacy in preventing joint damage and functional decline.
- Emerging therapies like cytokine antagonists (anti-tumor necrosis factor) necessitate updated clinical guidelines.
Purpose of the Study:
- To review recent advancements in understanding rheumatoid arthritis.
- To discuss epidemiological characteristics, economic impact, clinical progression, and therapeutic options for RA.
- To propose pharmacologic utilization models and interim treatment guidelines.
Main Methods:
- Literature review of recent developments in rheumatoid arthritis.
- Analysis of epidemiological data, economic costs, and clinical progression.
- Evaluation of current and emerging RA therapies, including cytokine antagonists.
- Development of pharmacologic utilization models and suggested interim treatment guidelines.
Main Results:
- Rheumatoid arthritis has profound individual and societal impacts.
- Existing RA therapies provide limited success in halting disease progression.
- Novel anti-tumor necrosis factor therapies present new challenges and opportunities for RA management.
- A comprehensive review of RA's multifaceted aspects is presented.
Conclusions:
- The emergence of biologic therapies like anti-tumor necrosis factor agents requires adaptation of RA treatment strategies.
- Further research and consensus are needed for comprehensive RA treatment recommendations.
- Interim guidelines are proposed to aid clinicians and managed care organizations in managing rheumatoid arthritis effectively.
- Understanding RA's epidemiology, cost, progression, and therapies is crucial for optimal patient care.